Illumina, Inc. (ETR:ILU)
72.42
+0.40 (0.56%)
May 13, 2025, 5:35 PM CET
Illumina Revenue
Illumina had revenue of $1.04B USD in the quarter ending March 30, 2025, a decrease of -3.25%. This brings the company's revenue in the last twelve months to $4.34B, down -3.47% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.34B
Revenue Growth
-3.47%
P/S Ratio
2.90
Revenue / Employee
$480.29K
Employees
9,030
Market Cap
11.61B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 23.14B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.33B |
Illumina News
- 1 day ago - Illumina Analysts Lower Their Forecasts After Q1 Results - Benzinga
- 1 day ago - Illumina Analysts Lower Their Forecasts After Q1 Results - Benzinga
- 2 days ago - Illumina: Multiple Headwinds Point To Limited Upside In 2025 - Seeking Alpha
- 4 days ago - Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions - Seeking Alpha
- 4 days ago - Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat - Seeking Alpha
- 12 days ago - Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development - PRNewsWire
- 22 days ago - Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know - Benzinga